Brii Biosciences Breakthrough Therapies Combat Hepatitis B

Brii Biosciences Limited, a leading biotech company, has recently been granted Breakthrough Therapy Designations by the Center for Drug Evaluation for two innovative therapies aimed at combating hepatitis B virus (HBV). The two investigational treatments, BRII-877 (tobevibart) and BRII-835 (elebsiran), have shown promising results in clinical trials.

BRII-877 has demonstrated significant reductions in HBsAg levels, while BRII-835 has displayed direct antiviral effects against HBV. These breakthrough designations mark a significant milestone in Brii Bio's mission to develop effective combination therapies for chronic HBV patients.

Hepatitis B is a major global health concern, affecting over 254 million individuals worldwide. Chronic HBV infection is a primary cause of liver disease, leading to approximately 820,000 deaths annually. In China alone, 87 million people are living with HBV.

Hepatitis D, a severe liver inflammation caused by the hepatitis D virus (HDV), poses a significant risk in individuals co-infected with HBV. The combination of HDV and HBV can accelerate liver-related complications and mortality rates. Nearly 5% of individuals with chronic HBV globally are impacted by HDV.

BRII-877, a monoclonal antibody, aims to prevent HBV and HDV from entering liver cells, potentially acting as a T-cell vaccine against these viruses. On the other hand, BRII-835, a small interfering RNA, triggers an immune response and exhibits direct antiviral properties against both HBV and HDV.

Brii Biosciences is committed to developing therapies for infectious diseases and central nervous system disorders, addressing critical medical needs and societal stigmas associated with these conditions.

The Breakthrough Therapy Designations granted to Brii Biosciences for their HBV treatments signify a significant advancement in the fight against hepatitis B. With ongoing research and upcoming combination studies, Brii Bio aims to optimize curative regimens and provide the best possible treatments for HBV patients worldwide.